Nymox Pharma Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study Of Fexapotide Triflutate In 146 US Men: 'Single-Treatment Leads to Long-Term 80% Reduction in Surgery and Radiotherapy...'